[go: up one dir, main page]

WO2009068278A3 - A pharmaceutical composition - Google Patents

A pharmaceutical composition Download PDF

Info

Publication number
WO2009068278A3
WO2009068278A3 PCT/EP2008/010051 EP2008010051W WO2009068278A3 WO 2009068278 A3 WO2009068278 A3 WO 2009068278A3 EP 2008010051 W EP2008010051 W EP 2008010051W WO 2009068278 A3 WO2009068278 A3 WO 2009068278A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
carnitine
men
acetyl
sexual dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/010051
Other languages
French (fr)
Other versions
WO2009068278A2 (en
Inventor
Anna Bozhek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Consumer Care AG
Original Assignee
Bayer Consumer Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EA200800221A external-priority patent/EA200800221A1/en
Application filed by Bayer Consumer Care AG filed Critical Bayer Consumer Care AG
Publication of WO2009068278A2 publication Critical patent/WO2009068278A2/en
Publication of WO2009068278A3 publication Critical patent/WO2009068278A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to medicine and, more particularly, to pharmaceutical compositions to prevent and treat sexual dysfunction in men. The pharmaceutical composition comprising compounds L-carnitine fumarate and L-carnitine acetyl hydrochloride, characterized in that the pharmaceutical composition comprises physiologically active substances in the following ingredient ratio (% w/w): L-carnitine fumarate (30) to (40), Acetyl L-camitine hydrochloride (10) to (15), Silicon (5) to (10), and further pharmacologically acceptable excipients. Thus, the pharmaceutical composition in accordance with the present invention makes it possible to ensure an effective prevention and treatment of sexual dysfunction in men as well as allows to provide an alternative medicament.
PCT/EP2008/010051 2007-11-30 2008-11-27 A pharmaceutical composition Ceased WO2009068278A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
UA200713326 2007-11-30
UA2007013326 2007-11-30
EA200800221 2008-01-31
EA200800221A EA200800221A1 (en) 2008-01-31 2008-01-31 PHARMACEUTICAL COMPOSITION

Publications (2)

Publication Number Publication Date
WO2009068278A2 WO2009068278A2 (en) 2009-06-04
WO2009068278A3 true WO2009068278A3 (en) 2009-12-23

Family

ID=40626947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/010051 Ceased WO2009068278A2 (en) 2007-11-30 2008-11-27 A pharmaceutical composition

Country Status (1)

Country Link
WO (1) WO2009068278A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027925A1 (en) * 1997-12-01 1999-06-10 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
US20060211721A1 (en) * 2005-03-21 2006-09-21 Roberts Alan R Nutraceutical formulation of a cognitive enhancement system
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027925A1 (en) * 1997-12-01 1999-06-10 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
US20060211721A1 (en) * 2005-03-21 2006-09-21 Roberts Alan R Nutraceutical formulation of a cognitive enhancement system
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COSTA M ET AL: "L-CARNITINE IN IDIOPATHIC ASTHENOZOOSPERMIA: A MULTICENTER STUDY", ANDROLOGIA, BLACKWELL, BERLIN, DE, vol. 26, 1 May 1994 (1994-05-01), pages 155 - 159, XP008014043, ISSN: 0303-4569 *
MONCADA M L ET AL: "EFFECT OF ACETYLCARNITINE TREATMENT IN OLIGOASTHENOSPERMIC PATIENTS", ACTA EUROPAEA FERTILITATIS, PICCIN MEDICAL BOOKS, PADOVA, IT, vol. 23, no. 5, 1 January 1992 (1992-01-01), pages 221 - 224, XP008014044, ISSN: 0587-2421 *

Also Published As

Publication number Publication date
WO2009068278A2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
NO20080827L (en) Solid dosage formulations of narcotic drugs that have improved buccal adsorption
EP2548552A3 (en) Titration package for 1-amino-alkylcylohexanes
WO2008023016A3 (en) Galenic formulations of aliskiren
ZA200810124B (en) Pharmaceutical combination comprising 3-(3-dimethyl-amino-1-ethyl-2-methyl-propyl)-phenol and Paracetamol
WO2010116385A3 (en) Pharmaceutical compositions for alleviating unpleasant taste
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
JP2012502047A5 (en)
MX2010003441A (en) Galenical formulations of organic compounds.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2005107810A3 (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
WO2008062475A3 (en) Pharmaceutical compositions of ursodiol
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2009019307A3 (en) Oral calcitonin compositions and applications thereof
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2008065144A3 (en) Galenic formulations of organic compounds
MX2007010886A (en) Acarbose methods and formulations for treating chronic constipation.
MX2010011193A (en) Liquid pharmaceutical composition for pain treatment and prevention.
RU2010154623A (en) Derivatives of 1-aminoalkylcyclohexane for the treatment of sleep disorders
JO3239B1 (en) Galenical Formulations of Organic Compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08855220

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08855220

Country of ref document: EP

Kind code of ref document: A2